drugset / Trial / NCT02248753

Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department

NCT02248753 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

A symptomatic episode of the heart rhythm disorder 'atrial fibrillation' (AF) is a frequent reason for visits to the emergency department. Currently, in the majority of cases, immediate (electrical or pharmacological) cardioversion is chosen, while atrial fibrillation terminates spontaneously in 70% of the cases within 24 hours. A wait-and-see approach with rate-control medication only, and when needed cardioversion within 48 hours of onset of symptoms, could be effective, safe and more cost-effective than current standard of care and could lead to a higher quality of life.

Timeline

Start
2014-10
Primary completion
2018-11
Completion
2019-12

Outcome

Met primary endpoint

paper a wait-and-see approach was noninferior to early cardioversion in achieving a return to sinus rhythm at 4 weeks. PMID 30883054 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amiodarone Small molecule — —
Subject Digoxin Other / unclassified — —
Subject Metoprolol Other / unclassified — —
Subject Verapamil Other / unclassified — —
Comparator flecainide Small molecule — —

Indications